Johnson & Johnson (NYSE:JNJ – Get Free Report) is scheduled to post its quarterly earnings results before the market opens on Tuesday, October 15th. Analysts expect Johnson & Johnson to post earnings of $2.19 per share for the quarter. Johnson & Johnson has set its FY24 guidance at $9.97-10.07 EPS and its FY 2024 guidance at 9.970-10.070 EPS.Individual that are interested in participating in the company’s earnings conference call can do so using this link.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.71 by $0.11. The business had revenue of $22.45 billion for the quarter, compared to analysts’ expectations of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company’s quarterly revenue was up 4.3% on a year-over-year basis. During the same period last year, the company earned $2.80 earnings per share. On average, analysts expect Johnson & Johnson to post $10 EPS for the current fiscal year and $11 EPS for the next fiscal year.
Johnson & Johnson Trading Up 0.6 %
JNJ opened at $161.46 on Monday. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The firm’s 50 day moving average is $162.59 and its 200-day moving average is $154.46. The firm has a market capitalization of $388.58 billion, a P/E ratio of 10.07, a P/E/G ratio of 2.65 and a beta of 0.52. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85.
Johnson & Johnson Dividend Announcement
Wall Street Analyst Weigh In
Several equities analysts have weighed in on JNJ shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Thursday. Royal Bank of Canada increased their target price on Johnson & Johnson from $175.00 to $178.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. TD Securities dropped their price target on Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Finally, Sanford C. Bernstein lifted their target price on Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Six equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $174.31.
Get Our Latest Analysis on JNJ
Insider Buying and Selling at Johnson & Johnson
In related news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.16% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Recommended Stories
- Five stocks we like better than Johnson & Johnson
- What Does Downgrade Mean in Investing?
- Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
- How to buy stock: A step-by-step guide for beginners
- Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.